GoodRx CMO Babak Azad departs; separation deal includes $205K lump sum, equity vest

GoodRx Holdings, Inc.

Azad's last day as CMO was July 7, 2023; separation agreement entered July 26, 2023.
Lump sum payment of $205,000; immediate vesting of 50,000 option shares and 20,402 RSUs.
Option exercise extended to 6 months post-separation; COBRA premium reimbursement for 9 months.
Mutual non-disparagement and full release of claims; agreement effective Aug 2, 2023 if not revoked.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Babak Azad

Chief Marketing Officer

GDRX · GoodRx Holdings, Inc.

Effective: 2023-07-07
Filed: July 27, 2023, 7:59 PM ET

As previously disclosed, on June 27, 2023, GoodRx Holdings, Inc. (the “ Company ”) determined that Babak Azad would no longer serve as Chief Marketing Officer and SVP, Marketing & Communications of the Company, effective July 7, 2023 (the “ Separation Date ”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Babak Azad departed as Chief Marketing Officer at GoodRx Holdings, Inc..

Action: departed
Role: Chief Marketing Officer

Exact text from the filing

As previously disclosed, on June 27, 2023, GoodRx Holdings, Inc. (the “ Company ”) determined that Babak Azad would no longer serve as Chief Marketing Officer and SVP, Marketing & Communications of the Company, effective July 7, 2023 (the “ Separation Date ”).

View on SEC.gov

GoodRx Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-025955

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.